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In developing countries international product development partnerships engage in health 
product innovation activities such as clinical trial research.  This paper discusses how one 
such partnership‟s (International AIDS Vaccine Initiative) activities build meso level 
institutional knowledge-based capacity between, and within, the Kenyan national level 
partners.  The paper will discuss the way knowledge is exchanged and how linkages are made 
between those involved in scientific research or innovation activities and those involved in 
healthcare activities within and beyond the partnership.  This research provides evidence of 
where these two fields of activity (innovation and health) need each other in order for AIDS 
vaccine clinical research to take place.  This paper outlines examples of this interconnectivity 
before discussing the questions this raises for the conceptualisation of the IAVI partnership, 
how this fits into a wider discussion regarding the definition of health innovation and how it is 
promoted within national and international policy spheres.   
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This paper discusses the results of a case study conducted of the International AIDS Vaccine 
Initiative and its activities in Kenya to conduct clinical research towards the development of 
an effective, affordable AIDS vaccine.  The search for an AIDS vaccine has been ongoing 
since the early 1980s.
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  Scientific dilemmas have hampered progress as recent collapse of the 
STEP trials and calls for return to basic science show (Fauci et al, 2008).  However, it is also 
possible to argue that the science of AIDS vaccine research is also hampered by 
organisational issues around how innovation takes place (Orsenigo et al, 2008; Chataway and 
Hanlin, 2008).  One starting place to study this is the work of the International AIDS Vaccine 
Initiative (IAVI).  IAVI was set up in 1996 as a not-for-profit (NFP) organisation based out of 
New York with the aim of promoting the development of an effective and affordable AIDS 
vaccine.  IAVI is the largest organisation focusing on HIV/AIDS vaccine research and is the 
second largest program after NIH (Priddy, 2007) but is dwarfed by NIH when compared in 
budget terms.  In 2005 total funding for HIV/AIDS vaccine R&D was estimated at $759 
million, provided mostly through US public funds ($574 million), of which 90% (US$ 511 
million) was accounted for by the NIH activities (HIV Vaccines and Microbicides Resource 
Tracking Working Group, 2006).  By comparison IAVI‟s projected spending for the next five 
years (2007 – 2011) is US$459 million and its individual revenues received for its HIV/AIDS 
vaccine development efforts were US$81 million in 2006 (IAVI, 2007).   
 
Part of the reason that IAVI is the largest organisation involved in AIDS vaccine research is 
that it focuses its activities on a number of different areas of the research-development-access 
continuum related to AIDS vaccine development and production.  From its headquarters in 
New York, IAVI oversees a number of different activities and works with a variety of 
partners to conduct those activities.  IAVI‟s activities take place in two arenas.  First, are 
those at a global level through the collaborations it has with its partners around the world.  
Secondly, there are its activities in individual countries.  These include its activities in the US 
but also those that occur in developing countries which are predominately managed through 
its regional offices that revolve around clinical trial research.   
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This study has looked at the work of IAVI and particularly its East African regional office‟s 
activities in Kenya. In Kenya IAVI partners with two public sector research organisations to 
conduct AIDS vaccine related clinical research, KAVI and KEMRI-CGMRC.  KAVI (the 
Kenyan AIDS Vaccine Initiative) is an institute housed within the Department of 
Microbiology at the University of Nairobi based within the grounds of Kenyatta National 
Hospital in Nairobi.  It came into being in the late 1990s following the decision to fund 
clinical trials of the first AIDS vaccine candidate in collaboration with the UK‟s MRC and 
IAVI funding.  KAVI as an organisation is wholly funded by IAVI‟s research money.  
KEMRI-CGMRC on the other hand is a centre within KEMRI, the country‟s national institute 
for health research which was founded with government backing in 1979.  The CGMRC is 
based in Kilifi and has long standing links with the UK‟s Wellcome Trust as well as other 
foreign research groups which have provided funding for various research projects 
supplementary to the government funding of its administration and staffing costs.  KEMRI-
CGMRC has an international reputation for this collaboration with the Wellcome Trust on 
malaria research and only became involved in AIDS vaccine work and IAVI from 2003.   
 
Fieldwork was carried out over a period of eight months during four trips in Kenya between 
October 2005 and November 2006.  During this time 55 semi-structured interviews were 
conducted with Kenya based representatives of the organisations involved in the IAVI 
partnership or involved in clinical research or vaccine development and the making of related 
policy in Kenya.  I supplemented this data with periods spent observing and „hanging around‟ 
(Bernard, 2006) IAVI‟s offices and those of their partner organisations collecting data.  Data 
analysis was conducted using a form of grounded theory approach whereby initial indexing 
and charting of emerging themes was gained from multiple readings of the data contents 




Three main examples were highlighted showing the interconnectivity between those involved 
in scientific research activities and those involved in healthcare provision to support AIDS 
vaccine clinical research activities in Kenya.  This is related to the way knowledge is 
exchanged and how linkages are made between those involved in scientific research or 




innovation activities and those involved in healthcare activities within and beyond the 
partnership. 
 
First, the data highlighted the need for discussions to take place between research and non-
research staff particularly those involved within local communities around the trial sites.  This 
is because in order for clinical trials to take place, there is not simply a need for scientific 
knowledge or lab based knowledge but also a range of other knowledge that relates to 
promoting the trials, gaining understanding, enrolment to the trials as well as promoting 
HIV/AIDS prevention activities alongside the clinical trials.    
 
Second, the research highlighted how although necessary, the interaction between those 
involved in scientific research and healthcare has increased as a result of the Kenyan IAVI 
partnership activities.  Not only has IAVI‟s activities in Kenya created an interaction between 
those involved around the trial sites from these different fields of activity but it has also led to 
the creation of a wider AIDS vaccine research network.  This has increased understanding of 
research activities within the local population living around the research sites and in the 
country more generally.  IAVI‟s policy and advocacy work through its regional office have 
assisted in the creation of a Kenyan HIV vaccine sub-committee (discussing regulatory and 
ethical issues of vaccine trials for example) that is the nodal point around which this wider 
network coalesces and operates from.   
 
Third, not only is there greater interaction between those involved in healthcare and research/ 
innovation activities around the trial sites there has been a cross-over of activities too.  The 
public sector research organisations conducting AIDS vaccine clinical research are now 
getting involved in healthcare activities.  They are working to strengthen healthcare facilities 
because they need stronger referral pathways as part of their clinical research activities.  
Where possible the research sites are trying to do this in partnership with existing care 
providers.  However, at times, they have set up their own care provision facilities in the short 
term as their local public healthcare facilities become resourced, usually financial and 









2.1 Discussion between research and non-research staff 
This research found that much of the activity within the trial sites took place around the 
laboratory.  This was partly the result of an emphasis within the clinical trial setting on forms 
and standard operating producers and has been discussed in depth elsewhere (see for example, 
Hanlin, 2008; Berg, 1998; Timmermans and Berg, 2003).  The focus on SOPs and forms 
creates a situation where it is possible to see the lab (perhaps in conjunction with the data 
management teams) as a central node within the clinical research site – and beyond within the 
wider IAVI partnership during discussions of clinical research data – as a result of its multiple 
interactions with others in the exchange of knowledge relating to clinical research information 
and data.  The result is that it becomes a „stabilising force‟ (Singleton, 1998) in its own right 
having the „situated‟ knowledge (Lave, 1993 in Quintas, 2002) required to, for example, 
translate data from a blood sample to the client report form and the authority required to work 
out any ambiguities relating to problem data entries.   
 
However, perhaps more interestingly, examples of process knowledge and information 
exchange move beyond and outside the research site itself and do not only occur between staff 
within the clinical trial site.  There is frequent discussion between the doctors/ nurses in the 
clinic and the community mobilisers, peer leaders and CAB members to gauge what was 
happening in the community within which the research trial site was situated.  It was widely 
acknowledged that this knowledge was invaluable and wide-ranging: 
“I was just reading a profile that our Amsterdam office sent us of one of the community 
mobilisers in Kangemi and she came with not only a wealth of experience but she knew 
Kangemi community like the back of her hand and I think that there‟s not much we can 
add to that kind of experience and that kind of knowledge, maybe some of the content 
pieces for sure but I think its much harder to get the community perspective… in terms 
of knowing the community and how to engage them, its process and materials specific.” 
[IAVI6] 
 
The community mobilisers act as knowledge brokers through their activities as I discuss in 
Section 5.3 of this chapter in more detail.  The role of community mobilisers here deserves 
special mention as they act not only as knowledge brokers but also as „translators‟ (c.f. Pigg, 




1995) of different notions of „development‟, „research‟ and „healthcare‟ from the research 
setting into the community setting and vice versa with positive and negative consequences. 
 
During my fieldwork I saw plenty of examples of where community mobilisers were regularly 
called upon to go into the community to find a volunteer who did not show up for a clinical 
trial appointment.  Their knowledge of the community means that they are more able to know 
exactly where to find a volunteer when addresses are not always accurate and trial participants 
may not be at home.  For example, on arriving at a trial site one morning I met two 
community mobilisers who were discussing the trials and tribulations of a visit to find a 
volunteer earlier that morning.  One of the community mobilisers had gone out to a 
community early in the morning to find the volunteer who had not shown up for a regular 
check up the previous week.  After driving around the community several times, she 
eventually found the volunteer and spent all morning persuading the volunteer, and more 
specifically, the volunteer‟s family that her illness (tonsillitis) was not due to the vaccine she 
had received and if it was that it would be okay because there were strict protocols relating to 
adverse reactions.  The volunteer was persuaded to remain in the study and to attend the clinic 
for her check-up appointment.  This was a relatively simple case.  In other situations, the 
community mobilisers had to call on their knowledge and skills much more intensively.  
When talking to a nurse at another site, I was told it took five attempts to find a volunteer who 
needed to be traced to receive a revised test result.   
 
It was also not only about the research itself whereby there was knowledge exchange.  For 
others, working in a clinical trial setting meant they interacted with the wider community in 
which the site was based in new ways and gained greater understanding of the community and 
of different ways of life: 
“I get to learn new things every day.  Initially I was working in Kilifi, which is a 
different setting altogether, that has a discordant couple [cohort] and it‟s a bit of a 
conservative society.  But once I moved here to Mombassa I found it‟s a different kind 
of thing altogether.  There are different people with different sexual orientations.  I have 
been able to accept that and I believe they have been able to accept me…” [Kilifi7] 
 
Each of these interactions created situations where knowledge was exchanged, learning took 
place and collaborative arrangements were solidified.  In some ways the actors involved in 




AIDS vaccine research in and around the trial site provide a similar make up to Wenger‟s 
(1998) concept of „Communities of Practice‟ (CoP).  CoPs are informal social networks of 
individuals who work together towards shared goals and with shared belief systems.  Shared 
experience within CoPs results in learning.  Groupings similar to CoPs, I would argue, appear 
to exist within the clinical trial sites which engage in IAVI clinical research made up of the 
doctors, nurses, lab and data technicians and community mobilisation personnel whose shared 
experience ensure knowledge is exchanged regarding the samples and data relating to a 
specific protocol.  They are however different from CoPs in that the emphasis on explicit data 
forms – on protocols, SOPs and GCP – creates a division of goals, beliefs and values within 
the clinical research „team‟.  The overt emphasis placed within these documents on strict 
divides between what is deemed research activities and health care provision activities creates 
difficulties for establishing shared beliefs and goals.   
 
2.2. Increased interaction creates wider ‘AIDS vaccine network’ 
Moving beyond the trial sites, I found that while not CoPs, other groupings of actors takes 
place – forced together due to the activities IAVI is funding around AIDS vaccine clinical 
research.  IAVI‟s activities have focused on building more local policy support within and 
around the communities in which trials take place.  It also involves building support within 
important stakeholder groups such as civil society organisations and healthcare practitioner 
communities.  This also involves building support within the government related policy arena.  
As a result of these activities there has been increased interaction and knowledge exchange 
between groups who in the past had worked separately and often unconnected with each other 
both in the research and policy arenas. 
 
One major example of this has been IAVI‟s influence on the policy environment within 
government circles around AIDS vaccine research activities. .  IAVI has supported the 
development of a national HIV vaccine research sub-committee and the development of 
research guidelines by this committee to provide a regulatory pathway for all vaccine 
research.  One IAVI member of staff told me that initially when the first vaccine trial had 
taken place there was no regulatory pathway in place and approval for the trial took nine to 10 
months.  Now, seven years later in 2006, it took just two to three months.  She stated this was 
partly because a regulatory pathway was now in place but also because vaccine research had 
become a source of national pride particularly as the first vaccine (developed jointly by the 




University of Oxford and the University of Nairobi) had been seen as a national product.  
Others also reiterated this informing me that the Government of Kenya had seen its ability to 
become a centre of excellence in (AIDS) vaccine development and as such the Government 
was particularly supportive to the activities and requirements of vaccine clinical research 
organisations.   
 
However, despite this there was a perceived lack of political will and unified approach 
towards clinical research in the country.  There was some acknowledgement, both by those 
working in the area of AIDS vaccine research and those working in the national health policy 
arena that I spoke to, that research was not high on the political agenda.  Treatment and the 
provision of ARVs were seen as being more important when it came to developing national 
HIV/AIDS policy while the universities were unable to invest in strategic research activities.  
I was also made aware of a lack of unity both nationally between research stakeholders but 
also at the level of the research sites.  When discussing the issue of national research policy I 
received a picture of a diverse set of national AIDS vaccine research stakeholders who all 
fought their corner to solidify their own positions before working together as a team to ensure 
research received more than a cursory mention in national policy documents.  No common 
reasoning was given for this but I understood the reasoning to be around different 
stakeholders wanting to retain, regain and justify their own positions and existence in terms of 
funding, reputation etc. 
 
More widely, IAVI is involved in the stimulation of a regional and international discussion of 
an AIDS vaccine research agenda.  IAVI staff work with African governments and the 
African AIDS Vaccine Programme to develop National AIDS Vaccine Plans and work to 
ensure that AIDS vaccine research does not get left out of regional and international policy 
discussions and related documents.  For example while I was in Kenya the regional office sent 
staff to Abuja to work with health ministers writing statements at UNGASS (the UN General 
Assembly Special Session on HIV/AIDS).  Furthermore, IAVI lobbies the East African 
parliament and national parliaments, workshops have been held in New York with WHO 
around vaccine regulation and IAVI‟s senior management are involved in international level 
debates around the financing of health research for neglected diseases.   
 
 




2.3 Crossover of activities 
Finally, collaboration and knowledge exchange around the trial sites has created a situation 
whereby there has been a crossover of activities whereby the clinical trial sites (often 
originally laboratory focused) have become providers of healthcare sometimes in paraellel to 
existing healthcare services available nearby.  This is perhaps inevitably with the subject 
matter of the research and partly as a result of a wider discussion on the ethics of clinical trials 
in developing countries (cf. Fitzgerald, Papea, et al., 2003; Fitzgerald and Wassuna, 2005; 
Weijer and LeBlanc, 2006).  This crossover of activities did not come easy to some of those 
that I spoke to and there was a divide within the staff at the clinical trial sites and IAVI about 
the extent to which these services were taken on as being part and parcel of the research 
process while others gave a moral argument regarding the need for this crossover of activities 
(sentiments such as the trial sites “can‟t not do it”). 
 
For whatever the reason, the trial sites in Kenya now either provide healthcare or provide 
strong referral pathways for volunteers and potential volunteers to receive treatment when 
needed at local facilities.  At the time of my fieldwork these healthcare activities took a 
variety of forms depending on the research site and whether the individual requiring care is a 
volunteer enrolled in a trial or a potential volunteer.  Volunteers, for example on receipt of 
initial test results back (for HIV, pregnancy etc) which take place as part of study enrolment, 
benefit from strong referral pathways put in place to enable these individuals to go to a public 
sector health service provider and receive follow up care and treatment.  For trial participants 
enrolled in a study most of their initial health needs are taken care of within the trial site 
facilities.  Sometimes this includes Anti-retroviral treatment for those who are or become HIV 
positive during the period of the trial.   
 
This situation means that trial sites have to consider a range of questions regarding their 
relationship and impact on local health facilities, their ability to provide care within economic 
trial restrictions, who they can provide care to (just trial participants or their families as well) 
and the state of current local health facilities.  Thus in some cases, IAVI has provided support 
to build, staff and maintain local dispensaries and ARV provision clinics rather than conduct 
these services in-house because of the implications this has on sustainability of local public 
health services.  However, at other times – when ARV supply chains have broken down – 




they have ended up becoming a provider for the short term while liaising with existing 





These examples highlight the importance of communication between scientific researchers 
within and around the trial sites, healthcare providers and others within a wider country level 
AIDS vaccine research network.  The activities of one trial site can not occur in isolation 
within the confines of „science‟ or „innovation‟.  The walls around clinical research have to be 
broken down.  My research of the IAVI partnership in Kenya outlined above highlights 
examples of where these two fields of activity, which are often viewed in separate spheres of 
policy and practice, are in fact heavily interconnected.  My research clearly shows how these 
two areas of research and healthcare are inseparable and need each other in order for AIDS 
vaccine clinical trial research to take place.   
 
This has implications for the way the IAVI partnership is conceptualised.  Recognition of 
these linkages emphasise the difficulty of separating research and care activities and how it is 
important, therefore, not to define health innovation simply in terms of R&D; in terms of 
what it takes to get a product produced.  It is also important to consider the wider players and 
processes that are necessary for ensuring successful health innovation.  Successful innovation 
requires more than simply the training up of scientists or even knowledge exchange and 
collaboration between scientists around trial sites.  It requires the recognition of a wider range 
of actors from community members to legislators and regulators.   
 
 
3.1 Value of innovation systems theory 
It is widely accepted within the innovation literature that although collaboration and 
knowledge exchange will take place as a natural activity because it has to (sic, the 
teleconference example above) innovation‟s potential will only be recognised if such 
knowledge exchange is encouraged and promoted (Carlsson and Stankiewicz, 1991; Clark, 
1985; Johnson and Lundvall, 2002; Lundvall, 1995; Narula, 2003).  Focusing on meso or 
organisational and macro enabling environment level capacity through the creation of 




organisational, learning and knowledge based connections will build generic competencies 
(Hawe, Noort, et al., 1997) and a learning function (Morgan, 2003) in order to do more than 
fix problems that arise in working towards goal attainment.  
 
Successful innovation, as has been recognised within innovation systems thinking, requires 
collaborative activity to build important organisational processes creating stronger institutions 
and enabling environments by increasing knowledge exchange (Lundvall, 2007).  As such in 
the health product innovation context it requires more than simply the training up of scientists 
or even knowledge exchange and collaboration between scientists around trial sites.  It 
requires the recognition of a wider range of actors from community members to legislators 
and regulators.   
 
In particular, the IAVI partnership in Kenya could be seen as providing an example of the role 
of what is termed „absorptive capacity‟ in innovation theory or, the ability of a firm to 
successfully acquire, assimilate, adapt and utilise knowledge acquired from external sources 
(Cohen and Levinthal, 1990).  This term can be used in the discussion of PPPs to describe the 
capacity of a partnership to manage knowledge (Hanlin, 2007).  The IAVI partnership is not a 
firm but IAVI, as the central node within the partnership operates similar to a virtual 
pharmaceutical company, effectively managing and manipulating knowledge between the 
various partner organisations.   
 
This is because IAVI works in ways similar to a virtual pharmaceutical company, it is 
possible to consider the role of IAVI as both a knowledge broker and integrator in relation to 
its activities and the workings of the partnership (Chataway, Brusoni, et al., 2007).  IAVI also 
acts as a knowledge broker in that it manages a diverse range of stakeholders each with 
different forms of knowledge that other partnership stakeholders need.  Chataway et al argue 
that this is particularly true of IAVI‟s advocacy work.  IAVI acts as an integrator in its 
vaccine innovation activities by not only contracting out research activities but manipulating 
knowledge internally, particularly through its advocacy activities, so that it can be more 
effectively used by others at different stages of the innovation chain.  Chataway et al contend 
that although IAVI does not call itself a knowledge broker or integrator, its ability to 
understand the value and use of knowledge are strongly evident in its activities 
internationally.   





This current Kenyan research shows that this is also the case in terms of the IAVI‟s activities 
at a country level in Kenya where there is a creation of absorptive capacity within the 
partnership as a result primarily of IAVI‟s knowledge management activities.  IAVI, without 
realising it, places an emphasis on knowledge which works to strengthen the linkages between 
those involved in the partnership.  This occurs in two ways.  
 
Firstly, IAVI is aware of the importance of ensuring knowledge transfer and communication 
at the country level.  IAVI sees the importance of training workshops as an avenue for 
information exchange outside of the formal teaching that takes place.  Similarly, while it 
encourages peer-to-peer learning having set up teleconferencing activities between lab staff 
around the multi-site studies it places less value on this.  Yet it works strongly to create 
understanding and awareness between those involved in the communities surrounding the trial 
sites and at the policy level.     
 
Secondly but less obviously, the activities and procedures put in place by IAVI at the research 
site – and which one IAVI manager termed its “systematising and operationalising” activities 
– have created a situation where multiple knowledge brokers exist and where knowledge 
brokering and transfer take place on a day-to-day basis.  For example, as part of the study I 
asked 25 people who worked in the research sites to map their day-to-day knowledge flows as 
a means of assisting my discussion.  The maps helped articulate different interactions and 
bring out details of with whom individuals talk, discuss with, learn from, pass 
information/knowledge to and what form this knowledge/information takes.  These maps 
provide an overview of the complex network of interactions as well as the knowledge and 
information flow that occurs within a certain section of the IAVI partnership (around the 
research centres).  PIs act as knowledge brokers between IAVI and the research centre staff 
providing the link by which study progress is passed to IAVI and new notifications of 
training, changes in protocol etc. are notified to staff.  The lab technicians act as knowledge 
brokers between the data (the samples) and the doctors/ nurses being able to explain what the 
data says (what knowledge the samples hold).  Finally, the community mobilisers act as 
brokers of community held knowledge to the research sites and of „scientific‟ knowledge to 
those outside the research sites. 
 




The IAVI partnership at country level in Kenya therefore does not appear to overtly focus on 
building institutional and organisational capacity at the meso level but does however conduct 
such activity.  In the same way other forms of capacity building more generally occur, 
institutional capacity is created as a result of working towards study progress; as part of the 
process towards goal attainment.  As one member of IAVI‟s staff told me: 
“You need someone to be able to support the training etc.  You can‟t just walk in and do 
a trial.  The staff have to have lots of training and establish all the procedures etc.  
Someone else could have done it… any other group.  All the other groups working in 
the developing world would have to have the same, you know, process. There is 
nowhere in the world that if the person hasn‟t done a clinical trial before you send them 
the protocol and say, „could you let me know when you have the data‟.  I mean, it 
doesn‟t work that way because good clinical practice, as you know, there are 
requirements and there are the requirements of the investigator but there are also the 
requirements of the sponsor.  So basically, we are just doing the same as we would in 
any country, we are going in and making sure you are covering all your responsibilities 
to conduct the research.” [IAVI2; emphasis added] 
 
The result is that IAVI can be said to end up „doing development without doing development‟ 
(Chataway, 2005).  It has characteristics of an international development organisation – which 
has the goals of capacity building, sustainability and integration – when it means to be an 
efficient business based model of partnership.  This tension is accepted within IAVI but also 
acknowledged to cause problems, as will be discussed in the next chapter.  An emphasis is 
placed on what is needed to arrive at the end point – the development of a vaccine.  The 
process taken is less important.  The result is that capacity building is seen as an input and not 
an important end in itself, despite what actually happens inadvertently in terms of institutional 
meso level capacity.  
 
Should IAVI choose to focus on capacity building more overtly, particularly on meso level 
institutional process capacity, this would open up an alternative means of evaluating the 
success of the partnership.  Focusing on outcomes rather than outputs and impacts may be 
useful for partnerships such as IAVI for two reasons.  Firstly, this makes sense practically as 
focusing on building institutional capacity creates the learning function that organisations 
need to build the generic competencies for true sustainability.  This is particularly necessary 




as working towards goal attainment does not happen in isolation of the social processes in 
which activities occur (Mosse, 2005).  The result is that for partnerships such as IAVI to 
“operate efficiently and effectively, they need to learn to adapt and change if they are to 
survive and prosper.” (Horton, Alexaki, et al., 2003: 37).  Secondly, it also provides a means 
for an organisation such as IAVI to work out the tensions of its development sector origins 
and objectives with its efforts to work using a private sector business model.   
 
3.2 Questions raised 
The IAVI partnership in Kenya highlights how health innovation activities involve an 
interaction between actors from these two different arenas that is more than simply seeing 
healthcare practitioners as receptors of a new health product.  They are in fact integral to their 
development; being part of a wider and interconnected health and research innovation system.  
Innovation of a new product must be seen through a wide lens that takes into account all 
aspects of a product‟s development including all the actors‟ interconnections from a diverse 
array of arenas who all at some point influence the scientific and technological trajectory of a 
product such as an AIDS vaccine  (Metcalfe, James, et al., 2005).  The starting point for 
moving towards such an inclusive approach is to bring together the different starting points of 
these two different arenas of health(care) and innovation and their respective policy 
prescriptions.   
 
These results raise a number of questions as to how the IAVI partnership is conceptualised 
and the wider health innovation discussion within national and international policy spheres.  
These questions relate to how health innovation is defined or is included into policy debates 
and which actors are involved.  As discussion around the term „health innovation‟ and „health 
research‟ gain prominence within international academic and policy arenas (Chataway, 
Chaturvedi, et al., 2007; Sadana and Pang, 2003) such questions have increasing relevance.   
 
Wider definitions of „health innovation‟ by Morel and others (cf. Morel et al, 2005; Mahoney 
and Morel, 2006) and „health research‟ by WHO and the Global Forum for Health Research 
(cf. Pang et al, 2003; Nuyens, 2005) allude to this need to be more inclusive.  They stress not 
only product development but also the wider enabling policy development.  However, as 
evidence from the IAVI partnership in Kenya validates, it is difficult to ensure a more 
inclusive approach focusing on the whole product development process is promoted even if it 




may be happening on the ground.  However, this is hindered by, a current emphasis on the 
end point; by a focus on goal orientation and a desire to get products out within IAVI which is 
briefly raised in the discussion surrounding the role of the trial sites in providing healthcare 
above.  The focus in this case is on capacity as access to products rather than a more holistic 
approach.  Such an approach would consider the strengthening of longer term capacity and 
building of linkages between the wide range of stakeholders that need to be involved to create 
sustainable capabilities.  
 
Focusing on the need to look holistically at all the actors involved and the type and form their 
connections take is similar to the emphasis placed within innovation systems on the 
importance of collaboration and knowledge exchange.  However, the difficulty of ensuring 
within the Kenyan IAVI partnership acknowledgement of these linkages and who is involved 
highlights the difficulty of identifying where the boundaries of such a system are.  This 
further highlights the requirements for, but difficulties associated with, innovation systems 
thinking that is being used to promote PDPs such as IAVI and from which the concept of 
health innovation systems was developed.  As IAVI‟s activities have developed over time in 
Kenya so the actors it has interacted with has changed.  While initially the partnership 
consisted of IAVI, the research organisations and trial site communities, it has since 
broadened out, partly through the creation of a wider country level AIDS vaccine research 
network including regulators, wider health care providers, government ministries and donors. 
 
This is where marrying innovation systems ideas with thinking from within the anthropology 
of development field (cf. Mosse and Lewis, 2006; is relevant.  Clark (2006) argues that 
innovation systems are viewed not as a concrete policy tool but should be used as metaphors 
for how innovation can be more successfully conducted.  Such a perspective, when added to 
an in-depth and critical analysis of power and politics flows from an anthropology of 
development perspective, creates a focus on the whole process of innovation and all the actors 
involved and not simply on getting products out; on goal orientation and the end point.  Such 
a perspective, which this study as a whole used, highlighted the interconnectedness of actors 
from within innovation and health in the area of AIDS vaccine clinical trials research in a way 
not acknowledged before.  In particular, it has highlighted the high degree of knowledge 
exchange and learning that takes place between actors within these two fields of activity and 




the importance this has on ensuring successful achievement of activities and the building of 





This paper has provided an overview of the way meso and macro level organisational and 
institutional collaboration and knowledge exchange have taken place within the setting of 
AIDS vaccine clinical research in Kenya.  It has also discussed how this takes place within the 
context of an external partner, IAVI, providing support to these activities.  This and foremost, 
this paper has provided evidence through this examination, along the lines of innovation 
systems thinking, that collaboration and knowledge exchange are not only important but 
imperative to the success of innovation activities.  However, underlying this has been an issue 
of power and politics that surround „partnership‟ and „collaboration‟ notions that is not often 
adequately addressed within innovation systems thinking.  Both of these issues raise questions 
about the way health innovation is being promoted, particularly at the policy level, and these 
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